Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check17 days agoChange DetectedThe page header now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedThis update shows a minor revision label change from v3.4.1 to v3.4.2. No substantive changes to the study details or eligibility criteria appear to have occurred.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous Revision: v3.4.0.SummaryDifference0.1%

- Check60 days agoChange DetectedUI updates include adding a 'Show glossary' option and modifying metadata labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and updating the revision to v3.4.0 (previously v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedDate fields on the study page were updated to include new last-update timestamps (e.g., 2026-01-16 and 2027-12-31) and the 'Last Update Posted (Estimated)' label. Some older update entries were removed.SummaryDifference0.4%

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.